Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model - An isobolographic analysis for parallel dose-response relationship curves

Pharmacology

Volumn 93, Issue 3-4, 2014, Pages 172-177

  Andres Mach, Marta ^a   Haratym Maj, Agnieszka ^a   Zagaja, Mirosław ^a   Luszczki, Jarogniew J ^a,b  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

1 Methyl 1,2,3,4 tetrahydroisoquinoline; Clobazam; Maximal electroshock induced seizures; Pharmacokinetic pharmacodynamic interactions

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; ANTICONVULSIVE AGENT; CLOBAZAM; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; 1-METHYL-1,2,3,4-TETRAHYDROISOQUINOLINE; BENZODIAZEPINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE; DRUG EFFECT; ELECTROSHOCK-INDUCED CONVULSION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SEIZURE; TONIC SEIZURE; ADULT; ANALYTIC METHOD; DRUG MIXTURE; DRUG POTENTIATION; ELECTRODE; ELECTROSHOCK SEIZURE; ISOBOLOGRAPHY; MAXIMAL ELECTROSHOCK INDUCED TONIC SEIZURE; NERVE STIMULATION; ANIMAL; DISEASE MODEL; DRUG COMBINATION; DRUG INTERACTION; ELECTRIC SHOCK; PATHOPHYSIOLOGY; SEIZURES;

ANIMALS; ANTICONVULSANTS; BENZODIAZEPINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROSHOCK; MALE; MICE; SEIZURES; TETRAHYDROISOQUINOLINES;

EID: 84900883120     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000360640     Document Type: Article

References (28)

1. Antkiewicz-Michaluk L, Wa̧sik A, Romańska I, Bojarski A, Michaluk J: Both stereoselective (R)-and (S)-1-methyl-1,2,3,4- tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release. Neurotox Res 2011; 20: 134-149.
2. Antkiewicz-Michaluk L, Karolewicz B, Romanska I, Michaluk J, Bojarski AJ, Vetulani J: 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 2003; 466: 263-269.
3. Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romaska I, Bojarski A, Vetulani J: Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 2004; 7: 155-163.
4. Antkiewicz-Michaluk L, Lazarewicz JW, Patsenka A, Kajta M, Zieminska E, Salinska E, Wasik A, Golembiowska K, Vetulani J: The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 2006; 97: 846-856.
5. Pietraszek M, Michaluk J, Romańska I, Wasik A, Goembiowska K, Antkiewicz-Michaluk L: 1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat. Neurotox Res 2009; 16: 390-407.
6. Antkiewicz-Michaluk L, Filip M, Michaluk J, Romańska I, Przegaliński E, Vetulani J: An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm 2007; 114: 307-317.
7. Luszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ: 1-Methyl-1,2,3,4- tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model. Neuropharmacology 2006; 50: 133-142.
8. Luszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ: Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2009; 602: 298-305.
9. Luszczki JJ, Antkiewicz-Michaluk L, Raszewski G, Czuczwar SJ: Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. Epilepsy Res 2010; 89: 207-219.
10. Andres-Mach M, Zadroniak A, Haratym-Maj A, Raszewski G, Antkiewicz-Michaluk L, Luszczki JJ: Effect of 1-methyl-1,2,3,4- tetrahydroisoquinoline on the protective action of various antiepileptic drugs in the maximal electroshock-induced seizure model: a type II isobolographic analysis. J Neural Transm 2013; 120: 1651-1663.
11. Larrieu JL, Lagueny A, Ferrer X, Julien J: Epilepsy with continuous discharges during slow-wave sleep. Treatment with clobazam (in French). Rev Electroencephalogr Neurophysiol Clin 1986; 16: 383-394.
12. Gastaut H, Tinuper P, Aguglia U, Lugaresi E: Treatment of certain forms of status epilepticus by means of a single oral dose of clobazam (in French). Rev Electroencephalogr Neurophysiol Clin 1984; 14: 203-206.
13. Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K: Use of clobazam for the treatment of refractory complex partial seizures. Seizure 2003; 12: 282-286.
14. Sanofi-Aventis. Frisium tablets 10 mg, summary of product characteristics from eMC. Electronic Medicines Compendium. Medicines. org.uk, 2002 (accessed July 11, 2005
15. Isojärvi JI, Tokola RA: Benzodiazepines in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 1998; 42(suppl 1):80-92.
16. Luszczki JJ, Borowicz KK, Swiader M, Czuczwar SJ: Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003; 44: 489-499.
17. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949; 96: 99-113.
18. Luszczki JJ, Czuczwar SJ: Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur Neuropsychopharmacol 2005; 15: 133-142.
19. Loewe S: The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953; 3: 285-290.
20. Porreca F, Jiang Q, Tallarida RJ: Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol 1990; 179: 463-468.
21. Ng YT, Collins SD: Clobazam. Neurotherapeutics 2007; 4: 138-144.
22. Doi T, Ueda Y, Tokumaru J, Willmore LJ: Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. Brain Res Mol Brain Res 2005; 142: 91-96.
23. Nakajima H: A pharmacological profile of clobazam (Mystan), a new antiepileptic drug (in Japanese). Nihon Yakurigaku Zasshi 2001; 118: 117-122.
24. Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L: Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol 1990; 29: 169-177.
25. McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, et al: Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000; 3: 587-592.
26. Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M: Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia 1996; 37: 728-735.
27. Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A: Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit 2002; 24: 737-741.
28. Cui D, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G: In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004; 32: 1279-1286.